Hims & Hers shares fall after a report says the FTC has investigated its cancellation policies and billing practices for over ...

Shares of Hims & Hers tumbled 12% in after-hours trading Monday after the company's second-quarter revenue missed Wall Street ...

Novo Nordisk , maker of the weight-loss drug Wegovy, has been sued in U.S. court by investors claiming the Danish ...

Investors with substantial losses have the opportunity (until August 25, 2025) to move the court for appointment as Lead Plaintiff. Shareholder rights firm Hagens Berman is investigating the legal ...

By Maggie Fick and Diana Novak Jones LONDON (Reuters) -In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and ...

HIMS investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

Through a trust, Dudum sold about $33.4 million worth of his company’s stock on Thursday, according to a filing with the ...

On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...

Business Economy Health Technology Hims & Hers’ ugly split with Wegovy maker weighs on the firm’s future July 7, 2025 at 6:00 am Updated July 7, 2025 at 6:00 am ...

SAN FRANCISCO, CA / ACCESS Newswire / July 21, 2025 / On June 25, 2025, securities class action lawsuits were filed against Hims & Hers Health, Inc. (NYSE:HIMS)and certain of the company's executives.

The pharma giant claimed that Hims & Hers was breaking the law by continuing to sell compounded semaglutide, the active ingredient in Novo’s Wegovy and Ozempic drugs, along with Novo's branded ...